KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Current Taxes (2017 - 2025)

Novartis Ag's Current Taxes history spans 9 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Current Taxes rose 23.14% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, up 23.14%, while the annual FY2025 figure was $2.0 billion, 23.14% up from the prior year.
  • Current Taxes for Q4 2025 was $2.0 billion at Novartis Ag, up from $1.6 billion in the prior quarter.
  • Across five years, Current Taxes topped out at $2.5 billion in Q4 2022 and bottomed at $1.6 billion in Q4 2024.
  • The 5-year median for Current Taxes is $2.0 billion (2025), against an average of $2.1 billion.
  • The largest annual shift saw Current Taxes fell 25.27% in 2023 before it rose 23.14% in 2025.
  • A 5-year view of Current Taxes shows it stood at $2.4 billion in 2021, then increased by 4.89% to $2.5 billion in 2022, then dropped by 25.27% to $1.9 billion in 2023, then decreased by 15.53% to $1.6 billion in 2024, then grew by 23.14% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Current Taxes are $2.0 billion (Q4 2025), $1.6 billion (Q4 2024), and $1.9 billion (Q4 2023).